Lilly Picked $2.8 Billion AtaiBeckley Deal for Short-Acting 5-MeO-DMT as GH Patent Fight Drags On
Updated
Updated · Psychedelic Alpha · Jul 24
Lilly Picked $2.8 Billion AtaiBeckley Deal for Short-Acting 5-MeO-DMT as GH Patent Fight Drags On
3 articles · Updated · Psychedelic Alpha · Jul 24
Summary
$2.8 billion of Lilly’s AtaiBeckley buyout was driven in part by interest in BPL-003’s short-acting 5-MeO-DMT profile, according to people familiar with the deal.
Lilly reportedly reviewed a broad psychedelic field—including public and private companies and candidates such as Compass’ COMP360—before settling on AtaiBeckley.
5-MeO-DMT’s brief duration appeared attractive because it could fit existing Spravato treatment infrastructure, though several industry sources questioned whether that model would work in practice.
GH Research still looms over the asset through an unresolved patent standoff, adding uncertainty as Lilly moves deeper into psychedelic drug development.